Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 26;25(1):668.
doi: 10.1186/s12872-025-05166-w.

Association between fibrosis-4 index and coronary heart disease: a population-based study

Affiliations

Association between fibrosis-4 index and coronary heart disease: a population-based study

Pan Jia et al. BMC Cardiovasc Disord. .

Abstract

Although the fibrosis-4 index (FIB‐4) was initially established as a liver fibrosis marker, recent studies have demonstrated its significant association with elevated risk of coronary artery disease(CHD). This study was conducted using data from five National Health and Nutrition Examination Surveys (NHANES) cycles between 2009 and 2018. Multivariable logistic regression analysis revealed a significant, positive relationship between FIB-4 and CHD.In sensitivity analyses, the highest FIB-4 quartile (Q4) showed a 4.22-fold increased CHD risk versus Q1 (OR = 4.22, 95% CI:1.93–9.24, P = 0.0005), with significant dose-response trends across quartiles (P < 0.05). Receiver operating characteristic (ROC) analysis revealed FIB-4 had good discriminative power for CHD (AUC = 0.80, 95%CI:0.78–0.81), with 75.9% sensitivity and 30.2% specificity at the optimal cutoff of 1.31. Restricted cubic splines (RCS) analysis revealed a nonlinear dose-response relationship between FIB-4 and CHD risk (P < 0.0001), with accelerated risk elevation beyond the inflection point (FIB-4 = 2.73). Subgroup analyses confirmed FIB-4’s robust association with CHD risk (overall OR = 1.66, 95%CI:1.57–1.76), with stronger effects in males (vs. females, Pinteraction = 0.042), non-diabetics (vs. diabetics, Pinteraction < 0.001), and racial minorities (highest OR = 2.36 in ‘Other Race’).These findings underscore the potential of FIB-4 as a novel biomarker for CHD risk assessment in clinical practice.

Keywords: Adults; Coronary heart disease; Cross-sectional analysis; FIB-4; NHANES.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The NHANES study protocol received approval from the National Center for Health Statistics Institutional Review Board, with all participants providing written informed consent in compliance with institutional and regulatory requirements. Consent for publication: Not applicable. Competing interests: The authors have no relevant financial or non-financial competing interests to declare.

Figures

Fig. 1
Fig. 1
Flow chart
Fig. 2
Fig. 2
ROC curves for FIB-4 to predict CHD. ROC, Receiver Operating Characteristic; AUC, area under the curve
Fig. 3
Fig. 3
RCS curves describing the dose–response relationship between FIB-4 and coronary heart disease
Fig. 4
Fig. 4
Subgroup analysis

References

    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. GBD-NHLBI-JACC global burden of cardiovascular diseases writing group. global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. - PMC - PubMed
    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–22. - PMC - PubMed
    1. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 heart disease and stroke statistics: A report of US and global data from the American heart association. Circulation. 2024;149(8):e347–913. - PMC - PubMed
    1. Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, et al. The association of Fibrosis-4 index scores with severe liver outcomes in primary care. J Gen Intern Med. 2022;37(13):3266–74. - PMC - PubMed
    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. - PMC - PubMed

LinkOut - more resources